ArticlePloS one2025
Enzymatic properties of a L-asparaginase without secondary glutaminase activity from Streptomyces scabrisporus.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel glutaminase-free l-asparaginase fromRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphocytic leukemia (ALL) is characterized by the uncontrolled proliferation of lymphocyte precursor cells within the bone marrow, blood and extramedullary sites. L-asparaginase has become a standard treatment in childhood cases of ALL by reducing the asparagine levels in the bloodstream on which leukemic cells depend, as they cannot synthesize it. The reduction of asparagine leads to cell cycle arrest and death by apoptosis. However, due to the bacterial origin of L-asparaginase, it causes immunogenic reactions, and the cross-glutaminase activity that the enzyme exhibits cause ammonium accumulation and toxicity in different organs and tissues. Enzymes with a lower immunogenic profile that preserve their affinity for the substrate asparagine and that do not have glutaminase activity are needed, such as L-asparaginases from Streptomyces scabrisporus or Rhizobium etli. In this work, the L-asparaginases from S. scabrisporus and R. etli were purified and characterized, and the kinetic parameters of the enzymes were compared under physiological conditions. Furthermore, both enzymes reduced the viability of MOLT-4 leukemic cells in a time- and concentration-dependent manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.